Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine for preventing respiratory failure in COVID-19 with fever (COLPREF)
jRCTs031210579Suspended
- Start
- Jan 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised trial in coronavirus disease 2019 (COVID-19) comparing Colchicine with Standard of care (2 arms). Primary endpoint: Use of oxygen (for 12 hours or longer) during admission or by Day 28. Started Jan 2022; status: suspended.
02
Drugs
colchicine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCTs031210579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031210579.